

PREFERENTIALLY  
RECOMMENDED BY ACIP  
FOR ADULTS 65+<sup>1</sup>

  
**FLUAD**<sup>®</sup>  
QUADRIVALENT  
influenza vaccine,  
adjuvanted

GIVE ADULTS 65 YEARS AND OLDER

# THE ADJUVANT ADVANTAGE<sup>\*1</sup>

\*Preferentially recommended by ACIP  
for adults 65+ over non-adjuvanted,  
standard-dose influenza vaccines.

ACIP=Advisory Committee on Immunization Practices

## INDICATIONS AND USAGE

FLUAD QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUAD QUADRIVALENT is approved for use in persons 65 years of age and older.

This indication is approved under accelerated approval based on the immune response elicited by FLUAD QUADRIVALENT. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

## IMPORTANT SAFETY INFORMATION

### CONTRAINDICATIONS

Severe allergic reaction to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

**Please see Important Safety Information throughout and full US Prescribing Information for FLUAD QUADRIVALENT.**

## DESIGNED TO ADDRESS 2 KEY CHALLENGES



### WEAKENED IMMUNE SYSTEM

Vaccine effectiveness may be reduced in adults 65+ as a result of a **weakened immune response** to vaccines<sup>2,3</sup>



### STRAIN MISMATCH


Strain mismatch, which occurred in 7 out of 10 flu seasons from 2010-2011 through 2019-2020, **may further reduce vaccine effectiveness**<sup>4-14</sup>

### WARNINGS AND PRECAUTIONS

If Guillain-Barré syndrome (GBS) has occurred within six weeks of receipt of prior influenza vaccine, the decision to give FLUAD QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

Please see Important Safety Information throughout and [full US Prescribing Information](#) for FLUAD QUADRIVALENT.

## ADJUVANTED TO BOOST THE IMMUNE RESPONSE<sup>15-18</sup>



See how adding MF59<sup>®</sup> Adjuvant does more than antigen alone.<sup>15-18</sup>



# CHOOSE THE ADJUVANT ADVANTAGE FOR YOUR PATIENTS 65+<sup>1</sup>



## ACIP Recommended

ACIP preferentially recommends FLUAD<sup>®</sup> QUADRIVALENT over standard-dose influenza vaccines for adults 65+.<sup>1</sup>

## Adjuvant Technology

Adding an adjuvant strengthens, broadens, and lengthens the immune response more than antigen alone.<sup>16-18</sup>

## Robust Response

FLUAD QUADRIVALENT produced a robust immune response against 4 strains in clinical trials and has a demonstrated safety profile.<sup>15</sup>

## Clinically Effective

20+ years of real-world evidence (RWE) in over 59 million patients supports the clinical effectiveness of the only adjuvanted flu vaccine for adults 65+.<sup>15,19-31</sup>

Contact your CSL Seqirus representative for more details  
or order FLUAD QUADRIVALENT on [flu360.com](https://www.flu360.com).

### WARNINGS AND PRECAUTIONS (continued)

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

Please see Important Safety Information throughout and [full US Prescribing Information](#) for FLUAD QUADRIVALENT.

### CPT CODE 90694:

0.5-mL pre-filled syringe  
10 syringes per carton



# FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted)

## INDICATION AND IMPORTANT SAFETY INFORMATION

CSL Seqirus

### INDICATIONS AND USAGE

FLUAD QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine. FLUAD QUADRIVALENT is approved for use in persons 65 years of age and older.

This indication is approved under accelerated approval based on the immune response elicited by FLUAD QUADRIVALENT. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

### IMPORTANT SAFETY INFORMATION

#### CONTRAINDICATIONS

Severe allergic reaction to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

#### WARNINGS AND PRECAUTIONS

If Guillain-Barré Syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

Syncope (fainting) may occur in association with administration of injectable vaccines including FLUAD QUADRIVALENT. Ensure procedures are in place to avoid injury from falling associated with syncope.

The immune response to FLUAD QUADRIVALENT in immunocompromised persons, including individuals receiving immunosuppressive therapy, may be lower than in immunocompetent individuals.

Vaccination with FLUAD QUADRIVALENT may not protect all vaccine recipients against influenza disease.

#### ADVERSE REACTIONS

The most common ( $\geq 10\%$ ) local and systemic reactions in elderly subjects 65 years of age and older were injection site pain (16.3%), headache (10.8%) and fatigue (10.5%). Other adverse events may occur.

**To report SUSPECTED ADVERSE REACTIONS, contact CSL Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 and [www.vaers.hhs.gov](http://www.vaers.hhs.gov).**

**Before administration, please see the [full Prescribing Information for FLUAD QUADRIVALENT](#).**

FLUAD® QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates.

#### For US Healthcare Professional Use Only

flu360, FLUAD QUADRIVALENT, and MF59 are registered trademarks of Seqirus UK Limited or its affiliates.

Seqirus USA Inc., 25 Deforest Avenue, Summit, NJ 07901, USA

©2023 Seqirus USA Inc. July 2023 USA-aQIV-23-0023

**References:** **1.** Grohskopf LA, et al. *MMWR Recomm Rep*. 2022;71(1):1-28. **2.** CDC. Flu & people 65 years and older. Accessed April 21, 2023. <https://www.cdc.gov/flu/highrisk/65over.htm> **3.** Monto AS, et al. *Vaccine*. 2009;27(37):5043-5053. **4.** Skowronski DM, et al. *PLoS One*. 2014;9(3):e92153. **5.** CDC. *MMWR Morb Mortal Wkly Rep*. 2011;60(21):705-712. **6.** Ohmit SE, et al. *Clin Infect Dis*. 2014;58(3):319-327. **7.** McLean HQ, et al. *J Infect Dis*. 2015;211(10):1529-1540. **8.** Gaglani M, et al. *J Infect Dis*. 2016;213(10):1546-1556. **9.** Zimmerman RK, et al. *Clin Infect Dis*. 2016;63(12):1564-1573. **10.** Jackson ML, et al. *N Engl J Med*. 2017;377(6):534-543. **11.** Rolfes MA, et al. *Clin Infect Dis*. 2019;69(11):1845-1853. **12.** Flannery B, et al. *J Infect Dis*. 2020;221(1):8-15. **13.** Tenforde MW, et al. *Clin Infect Dis*. 2021;73(11):e4244-e4250. **14.** Zost SJ, et al. *Proc Natl Acad Sci USA*. 2017;114(47):12578-12583. **15.** FLUAD QUADRIVALENT. Package insert. Seqirus Inc. **16.** O'Hagan DT, et al. *Vaccine*. 2012;30(29):4341-4348. **17.** O'Hagan DT, et al. *Expert Rev Vaccines*. 2013;12(1):13-30. **18.** Banzhoff A, et al. *Influenza Other Respir Viruses*. 2008;2(6):243-249. **19.** Izurieta HS, et al. *Clin Infect Dis*. 2021;73(11):e4251-e4259. **20.** Izurieta HS, et al. *J Infect Dis*. 2020;222:278-287. **21.** Boikos C, et al. *Clin Infect Dis*. 2021;73(5):816-823. **22.** Izurieta HS, et al. *J Infect Dis*. 2019;220:1255-1264. **23.** Pelton SI, et al. *Vaccines (Basel)*. 2020;8(3):E446. **24.** McConeghy KW, et al. *Clin Infect Dis*. 2021;73(11):e4237-e4243. **25.** Cocchio S, et al. *Vaccines*. 2020;8(3):344. **26.** Van Buynder PG, et al. *Vaccine*. 2013;31(51):6122-6128. **27.** Mannino S, et al. *Am J Epidemiol*. 2012;176(6):527-533. **28.** Lapi F, et al. *Expert Rev Vaccines*. 2019;18(6):663-670. **29.** Pelton SI, et al. *Vaccine*. 2021;39(17):2396-2407. **30.** van Aalst R, et al. *Vaccine*. 2020;38(2):372-379. **31.** Data on file. Seqirus Inc; 2022.